New sleep aid trial targets lingering insomnia in depression
NCT ID NCT06843187
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study tests if Lemborexant, a sleep medication, can improve sleep in adults whose depression is already treated but who still have insomnia. About 30 participants will take either the drug or a placebo daily for 6 weeks, tracking sleep with diaries and a wearable device. The goal is to see if the drug is practical, tolerable, and effective for this specific problem.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INSOMNIA COMORBID TO PSYCHIATRIC DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St. Michael's Hospital, Unity Health Toronto
Toronto, Ontario, M5B 1W8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can couples counseling lift depression in women?
- Brain wave clues: could inflammation markers forecast ECT outcomes?
- Can tailored brain zaps beat standard therapy for depression?
- Can a new daily pill lift the fog of depression?
- Can a new pill outsmart depression? a trial puts KH607 to the test
- Depression's biological fingerprint: a quest for objective diagnosis and personalized treatment